Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P22760

UPID:
AAAD_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P22760; A8K3L3; D3DNJ6; Q8N1A9

BACKGROUND:
The Arylacetamide deacetylase enzyme, with the unique identifier P22760, is integral to liver function, facilitating the breakdown of triglycerides into fatty acids for very low-density lipoprotein production. It also exhibits serine esterase activity and plays a pivotal role in the deacetylation of various arylacetamide substrates, transforming them into more toxic arylamide compounds.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Arylacetamide deacetylase offers a pathway to novel therapeutic approaches. Its critical role in lipid metabolism and the detoxification of harmful compounds highlights its potential as a therapeutic target in liver-related disorders and toxicity management.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.